CXCL13: A promising drug target and biomarker for the treatment of inflammatory diseases

Target Name: CXCL13

NCBI ID: G10563

CXCL13

CXCL13: A promising drug target and biomarker for the treatment of inflammatory diseases

The production and function of cytokines are crucial for the regulation of immune and inflammatory responses. Small-inducible cytokines (SICs), such as CXCL13, play a vital role in the immune response by modulating the recruitment and activation of immune cells. CXCL13 is a cytokine that has been identified as a potential drug target and biomarker for the treatment of inflammatory diseases, including chronic obstructive pulmonary disease (COPD), rheumatoid arthritis (RA), and inflammatory bowel disease (IBD).

CXCL13: A potent cytokine

CXCL13 is a single-chain cytokine that is expressed in various tissues and cells, including macrophages, dendritic cells, and epithelial cells. It is characterized by a unique N-terminal signaling domain that consists of a leucine-rich repeat (LRR) and a cytoplasmic domain. The LRR is involved in the formation of a complex with the protein Fc-??R1 and plays a critical role in the regulation of cellular processes, including cell adhesion, migration, and cytokine signaling.

CXCL13 has been shown to play a pivotal role in the regulation of inflammation and immune cell function. It has been shown to promote the recruitment of immune cells to sites of infection or injury, thereby contributing to the development of inflammatory diseases. CXCL13 has also been shown to regulate the activation and function of immune cells, including T cells, B cells, and macrophages.

CXCL13 as a drug target

The potential use of CXCL13 as a drug target is based on its ability to modulate the functions of immune cells and its potential role in the development of inflammatory diseases. Several studies have demonstrated that inhibition of CXCL13 can suppress the production of pro-inflammatory cytokines and improve the therapeutic response to inflammatory diseases.

One of the potential mechanisms by which CXCL13 may work as a drug target is by modulating the production of pro-inflammatory cytokines. CXCL13 has been shown to stimulate the production of pro-inflammatory cytokines, including TNF-?±, IL-1??, and IL-6, by immune cells such as T cells and B cells. By inhibiting the production of these cytokines, CXCL13 may have a therapeutic effect on the development of inflammatory diseases.

Another potential mechanism by which CXCL13 may work as a drug target is by modulating the function of immune cells. CXCL13 has been shown to promote the recruitment of immune cells to sites of infection or injury, thereby contributing to the development of inflammatory diseases. By inhibiting the recruitment of immune cells to these sites, CXCL13 may have a therapeutic effect on the development of inflammatory diseases.

CXCL13 as a biomarker

The potential use of CXCL13 as a biomarker for the diagnosis and monitoring of inflammatory diseases is based on its ability to regulate the production of pro-inflammatory cytokines and its potential role in the development of these diseases. Several studies have demonstrated that the levels of CXCL13 are significantly increased in individuals with inflammatory diseases, such as COPD, RA, and IBD. By measuring the levels of CXCL13 in individuals with inflammatory diseases, CXCL13 may be used as a biomarker for the diagnosis and monitoring of these diseases.

Conclusion

CXCL13 is a potent cytokine that plays a crucial role in the regulation of the immune response and the development of inflammatory diseases. Its potential as a drug target and biomarker make it an attractive target for the development of new therapies for the treatment of inflammatory diseases. Further research is needed to fully understand the role of CXCL13 in

Protein Name: C-X-C Motif Chemokine Ligand 13

Functions: Chemotactic for B-lymphocytes but not for T-lymphocytes, monocytes and neutrophils. Does not induce calcium release in B-lymphocytes. Binds to BLR1/CXCR5

The "CXCL13 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CXCL13 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets